Bempedoic Acid
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Bempedoic Acid |
| DrugBank ID | DB11936 |
| Brand Names (EU) | Nilemdo |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.61% |
Approved Indication (EMA)
Hypercholesterolaemia and mixed dyslipidaemiaNilemdo is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non familial) or mixed dyslipidaemia, as an adjunct to diet:• in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL C goals with the maximum tolerated dose of a statin (see sections 4.2, 4.3, and 4.4) or,• alone or in combination with other lipid-lowering therapies in patients who are statin intolerant, or f
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | hyperthyroidism | 99.61% | DL |
| 2 | resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta | 99.58% | DL |
| 3 | malignant catarrh | 99.58% | DL |
| 4 | infectious bovine rhinotracheitis | 99.58% | DL |
| 5 | cytomegalovirus infection | 99.53% | DL |
| 6 | homozygous familial hypercholesterolemia | 99.48% | DL |
| 7 | hyperthyroxinemia | 99.34% | DL |
| 8 | drug-induced osteoporosis | 99.21% | DL |
| 9 | multiple endocrine neoplasia | 99.18% | DL |
| 10 | pregnancy associated osteoporosis | 99.17% | DL |
| 11 | postmenopausal osteoporosis | 99.12% | DL |
| 12 | acne (disease) | 98.98% | DL |
| 13 | autosomal dominant neovascular inflammatory vitreoretinopathy | 98.95% | DL |
| 14 | Worth syndrome | 98.88% | DL |
| 15 | Graves disease | 98.70% | DL |
| 16 | hypoalphalipoproteinemia | 98.70% | DL |
| 17 | succinyl-CoA:3-ketoacid CoA transferase deficiency | 98.69% | DL |
| 18 | cholestasis | 98.66% | DL |
| 19 | non-syndromic visceral malformation | 98.63% | DL |
| 20 | biliary atresia intrahepatic | 98.55% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.